NYSE:KDMN - Kadmon Stock Price, Forecast & News

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Kadmon Holdings Inc (NYSE:KDMN) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.31. The firm earned $0.23 million during the quarter, compared to analysts' expectations of $0.29 million. Kadmon had a negative return on equity of 188.03% and a negative net margin of 9,855.14%. View Kadmon's Earnings History.

Kadmon is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Kadmon.

5 brokerages have issued 12 month target prices for Kadmon's shares. Their forecasts range from $2.77 to $25.00. On average, they expect Kadmon's stock price to reach $10.75 in the next year. This suggests a possible upside of 136.9% from the stock's current price. View Analyst Price Targets for Kadmon.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon.

Headlines about KDMN stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kadmon earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Kadmon.

Kadmon saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,130,000 shares, an increase of 46.1% from the December 15th total of 9,670,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the days-to-cover ratio is currently 8.1 days. Approximately 12.1% of the shares of the company are short sold. View Kadmon's Current Options Chain.

Some companies that are related to Kadmon include Ra Pharmaceuticals (RARX), Synthorx (THOR), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Heron Therapeutics (HRTX), Insmed (INSM), Cambrex (CBM), Ironwood Pharmaceuticals (IRWD), Principia Biopharma (PRNB), Pacira Biosciences (PCRX), Forty Seven (FTSV) and Zymeworks (ZYME).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Applied Materials (AMAT), Iovance Biotherapeutics (IOVA), Biocept (BIOC), Global Blood Therapeutics (GBT), Bristol-Myers Squibb (BMY), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Cidara Therapeutics (CDTX) and Fate Therapeutics (FATE).

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KDMN stock can currently be purchased for approximately $4.54.

Kadmon has a market capitalization of $588.79 million and generates $1.40 million in revenue each year. The company earns $-54,250,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Kadmon employs 116 workers across the globe.View Additional Information About Kadmon.

The official website for Kadmon is http://www.kadmon.com/.

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at ellen.cav[email protected]